MichaelVChioreanMD

Gastroenterology • Issaquah, WA

Advanced Endoscopic Interventional, Inflammatory Bowel Disease

Physician

Join to view full profile

Dr. Chiorean is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Chiorean's full profile

Already have an account?

Office
751 NE Blakely Dr #3020
Ste 3020
Issaquah, WA 98029
Phone+1 206-215-4250

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 2000 - 2003
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1998 - 2000
Corewell Health East Beaumont (Royal Oak)Internship, Internal Medicine, 1997 - 1998
Iuliu Hatieganu University of Medicine and PharmacyClass of 1992

Certifications & Licensure

WA State Medical License 2012 - 2025
TX State Medical License 2023 - 2023
IN State Medical License 2004 - 2013
OH State Medical License 2004 - 2007
MN State Medical License 1999 - 2005
MI State Medical License 1997 - 1998
American Board of Internal Medicine Gastroenterology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification HealthSentry EHR, Cerner Corporation, 2013
Fellow (AGAF) American Gastroenterological Association, 2011

Clinical Trials

Chromoendoscopy for Ulcerative Colitis Surveillance Start of enrollment: 2005 Dec 01
Completed
Can CT Enteroclysis Predict the Outcome of Crohn's Disease Start of enrollment: 2007 Aug 01
Completed
Prevalence of Lymphoma in IBD Start of enrollment: 2006 Apr 01
Completed
Value of Fecal Calprotectin Start of enrollment: 2006 Apr 01
Completed
Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis Start of enrollment: 2013 Nov 01
Terminated
Phase 2
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease Start of enrollment: 2020 Jun 22
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Etrasimod as a Monotherapy or With Concomitant Use of Corticosteroids and/or Aminosalicylates: Results From the ELEVATE UC Clinical Program.
Andres J Yarur, Michael V Chiorean, Jessica R Allegretti, Raymond K Cross, Christina Ha
Inflammatory Bowel Diseases. 2024-12-13
1 citations
Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
Séverine Vermeire, Bruce E Sands, Laurent Peyrin-Biroulet, Geert R D'Haens, Julian Panés
Journal of Crohn's & Colitis. 2024-11-04
Postvaccination Symptoms After a Fourth Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease.
Yoo Jin Lee, Dalin Li, Angela Mujukian, Philip Debbas, Melissa Hampton
Inflammatory Bowel Diseases. 2024-08-01

Press Mentions

FDA Approves Zeposia for Moderate-to-Severe Ulcerative ColitisMay 28th, 2021
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (Ozanimod), an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1May 27th, 2021
One Physician's Take on CME in the Era of COVID: ACG 2020November 9th, 2020
Join now to see all

Professional Memberships